1. Media & Marketing

Drug Channels News Roundup, July 2022: CVS vs. NACDS, ICER Impact, Biosimilar Boom, Deductible Doubts, and Alto Pharmacy (and me)

Cut through the steamy summer haze with our refreshing selection of articles and insights. In this issue:

  • CVS disassociates itself from its chain pharmacy association
  • Payers are paying attention to ICER
  • Benefits of the biosimilar boom
  • A fantastic takedown of health insurance deductibles

Plus, I join the Advisory Board of Alto Pharmacy.

P.S. Join my nearly 30,000 (!) LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter, where I have more than 14,700 followers.

Join me next week for my new live video webinar, Specialty Drugs Update: Trends, Controversies, and Outlook, on July 29, 2022, from 12:00 p.m. to 1:30 p.m. ET. I’ll cover market trends, payer strategies, channel developments, key trends that will help you plan for the future, and more. Click here for details and registration info.

Read more »

View Original Article
Do you like Drug Channels's articles? Follow on social!